OrbiMed Buys $3.6M of Electra Therapeutics Open-Market Days After IPO
ETRA is trading near its 52-week low of $6.865 (7.1% above the low).
Summary
OrbiMed Advisors bought 472,571 ETRA shares for $3.6 million in the open market on Nov 3-5 at $7.07-$7.88, well under the $15.00 September IPO price, raising its stake to 5,220,762 shares.
Key Events · Ownership and Investor Activity · ETRA
-
OrbiMed Adds 472,571 Shares
Ten open-market purchases on 2026-11-03 to 2026-11-05 totaled 472,571 shares for $3,605,116.39, at prices from $7.07 to $7.88.
-
Stake Rises to 5.22M Shares
Post-transaction holdings reached 5,220,762 shares, split between OrbiMed Private Investments VII and OrbiMed Genesis Master Fund.
-
Buys Priced Below IPO
Purchases at $7.07-$7.88 compare with the $15.00 per-share IPO pricing disclosed in the September 424B4, so the sponsor is averaging down.
-
Sponsor, Not Operator
OrbiMed is a director and 10% owner; the buying reflects portfolio conviction rather than an executive's view of day-to-day operations.
Analysis · ETRA · Life Sciences
OrbiMed, a director and 10% owner, put $3.6 million of real money into ETRA across three sessions at $7.07-$7.88 a share — below the $15.00 IPO price set in September. That is a meaningful vote of confidence from the sponsor that built the position out of preferred stock, and it comes while the stock trades at roughly half its IPO level. The buying is spread across two OrbiMed vehicles and lifts combined holdings to 5,220,762 shares. The caveat is that this is a financial sponsor, not an operating executive, so the read-through is about valuation support rather than inside knowledge of the drug pipeline.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETRA was trading at $7.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $461.3M. The 52-week trading range was $6.87 to $15.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.